TABLE 4.

Relative pharmacokinetic parameters of probe substances in male and female rats exposed to Na-DHA.

		t1/2 (h)	tmax (h)	Cmax (mg/L)	AUC (mg/L*h)	Vz (L/kg)	Cl (L/h/kg)	MRT (h)
Phenacetin CYP1A2	♀	1.40 ± 0.56	2.29 ± 0.69	1.63 ± 0.38	2.45 ± 0.68	0.58 ± 0.12	0.44 ± 0.15	1.53 ± 0.40
	♂	1.47 ± 0.19	1.63 ± 0.48	0.80 ± 0.23*	1.24 ± 0.38*	1.37 ± 0.49*	0.85 ± 0.25	1.45 ± 0.22
Omeprazole CYP2D1/2	♀	1.72 ± 0.43	1.80 ± 0.32	1.80 ± 0.50	3.26 ± 1.23	0.59 ± 0.20	0.48 ± 0.24	1.71 ± 0.31
	♂	0.70 ± 0.08*	0.71 ± 0.19*	0.93 ± 0.19*	0.90 ± 0.36*	0.86 ± 0.25	1.12 ± 0.48	1.67 ± 0.36
Chlorzoxazone CYP2E1	♀	0.92 ± 0.05	1.40 ± 0.48	0.89 ± 0.28	1.17 ± 0.31	0.90 ± 0.32	0.86 ± 0.27	1.01 ± 0.05
	♂	1.62 ± 0.51	0.30 ± 0.00*	0.62 ± 0.22	0.89 ± 0.33	1.90 ± 0.71	1.24 ± 0.42	1.65 ± 0.46
Dapsone CYP3A1/2	♀	1.12 ± 0.54	1.33 ± 0.00	1.73 ± 0.43	2.96 ± 1.14	0.41 ± 0.11	041 ± 0.17	1.47 ± 0.70
	♂	1.32 ± 0.35	0.44 ± 0.18*	0.80 ± 0.20**	0.96 ± 0.39*	1.17 ± 0.34*	0.80 ± 0.33	1.28 ± 0.34

Note: The four probe substances were administered by lavage at 24 h after rats were given 200 mg/kg Na-DHA for five consecutive days, and blood samples were collected at different time points during 0∼24 h. Data in Table 3 show the ratios of pharmacokinetic parameters in Na-DHA-treated animals compared to those in normal controls, based on the pharmacokinetic analysis by Winnonlin5.3 for the plasma probe concentration of six males or six females by HPLC determination.

*p < 0.05, **p < 0.01, compared to females.